All SARS-CoV-2 articles
-
NewsStudy confirms effectiveness of medicinal plant against SARS-CoV-2 virus
A study has revealed that galloylquinic acids extracted from the leaves of Copaifera lucens Dwyer, a tree endemic to Brazil primarily found in the Atlantic Forest, have a multi-targeted effect against SARS-CoV-2, the virus that causes COVID-19.
-
NewsNew study shows antibodies need a strong core — not just grip — to fight SARS-CoV-2
Researchers used advanced computer simulations to investigate how antibody–virus complexes respond to mechanical forces across multiple SARS-CoV-2 variants, including the original 2019 strain and Omicron subvariants BA.4 and JN.1.
-
NewsThe handbook that can prepare countries for the next pandemic
A new handbook has been published to pave the way for better decision-making and greater preparedness for the next pandemic. It provides practical guidance on how mathematical models can be used to inform decision-making, and how the results can be communicated in times of crisis.
-
NewsCOVID-19 and severe heart attack increase mortality by 25% after one year, more than double pre-pandemic rates
Findings from the North American COVID-19 Myocardial Infarction (NACMI) registry demonstrate significantly higher one-year mortality rates in patients with COVID-19 and ST-elevation myocardial infarction (STEMI) compared to patients with STEMI alone.
-
NewsSARS-CoV-2 does not persist in the placenta after maternal recovery from COVID-19
A new study finds that the virus that causes COVID-19 does not linger in placental tissue weeks to months after a pregnant woman recovers from infection - offering important reassurance for clinicians and patients alike.
-
NewsCOVID antiviral speeds recovery but doesn’t reduce hospitalization in vaccinated patients, trials find
Paxlovid (nirmatrelvir-ritonavir) does not reduce hospital admissions or deaths in vaccinated adults at higher risk of severe COVID-19, despite helping them recover faster, according to results from two national trials.
-
NewsStudying two very different viruses helps to develop new strategies
When the SARS-CoV-2 pandemic began, virologist Theodora Hatziioannou, in conjunction with Paul Bieniasz brought her HIV-honed skills and tools to this new global threat, which made it easier and faster for researchers to gain insights into the virus and test antibodies for potential therapeutic candidates in real time.
-
FeaturesClinical considerations for the next pandemic: challenges facing Japan and strategic preparedness
Multiple global pandemics over the past century – the Spanish influenza (1918), Asian influenza (1957), Hong Kong influenza (1968), H1N1 influenza (2009), and COVID‑19 (since 2019) – have increasingly underscored the necessity for healthcare systems worldwide to be resilient, rapidly responsive, and forward‑facing.
-
NewsA closer look at immune ‘memory’ - and how long it lasts
A new review shares recent advances from the field of immune memory and highlights key steps we might take to develop even more effective, longer-lasting immunity against deadly diseases.
-
NewsResearchers explore potential link between COVID-19 and lung cancer risk
New findings have identified a potential association between COVID-19 and increased lung cancer risk, driven by underlying biological mechanisms in the lung. The study integrates human clinical data with mechanistic research in animal and cellular models.
-
NewsLong COVID associated with increased risk of cardiovascular disease
People with long COVID are at increased risk of developing cardiovascular disease, according to a new study. Women with long COVID had just over twice the risk of receiving a cardiovascular diagnosis compared with women without long COVID. Men had approximately a third higher risk.
-
NewsNew vaccine strategy could help extend immunity against evolving viruses
Researchers have identified a possible way to make longer lasting vaccines for respiratory viruses like influenza and the coronavirus that causes COVID-19.
-
NewsAging lung cells could be why COVID and flu are so dangerous to the elderly
Older adults are much more likely to become seriously ill from flu or COVID because aging lung cells can drive excessive immune responses, according to a new study led by researchers.
-
NewsGenetic breakthrough uncovers evolutionary limits of the COVID-19 virus
A new paper indicates that while the COVID-19 virus has developed rapidly since 2019, it has done so within limited genetic channels. These genetic limits have remained unchanged.
-
NewsAutoantibodies implicated as drivers of long COVID in new study
A new study shows that antibodies from Long COVID patients can induce persistent pain-like symptoms in mice. This provides evidence for a potential causal role of autoantibodies in Long Covid.
-
NewsStudy details neuropsychiatric symptoms and biological mechanisms of long COVID
A review highlights the need to standardize diagnosis and treatment of long Covid. In the study, the researchers emphasize that avoiding SARS-CoV-2 infection is the only way to prevent long COVID so far.
-
NewsNew study reveals spleen-to-lung neutrophil axis orchestrates antiviral defense
Single-cell spatial mapping uncovers the spleen as a critical reservoir for lung neutrophils during respiratory viral infection, according to a new study.
-
NewsNovel biosensing platform enables fingertip blood-based micro-volume t-cell immune monitoring
A new platform, known as Tip Optofluidic Immunoassay Interferon-Gamma Release Assay (TOI-IGRA), could revolutionize how people monitor their immune health. The platform allows for the precise quantification of pathogen-specific T-cell responses using a mere 15-25 μL of fingertip blood.
-
NewsInappropriate antibiotic use for COVID-19 is linked to resistance
Taking azithromycin for as little as one day triggers antibiotic resistance in the respiratory tract, according to a first-of-its kind look by scientists at the changes that occur in the microbiome of hospitalized patients who were treated for COVID-19.
-
NewsTrial finds vitamin D supplements don’t reduce Covid severity but could reduce long COVID risk
In a large, randomized trial, researchers have found that high-dose vitamin D3 did not reduce COVID-19 infection severity, but may impact long COVID outcomes.